Zymeworks Inc (ZYME)

[Brokemillwright]

From a newsletter, stock hasn't been a performer bit it's more of a speculation play. Valued at $50 a share for buyout, but before the 100m offering they just did.

Large pharmaceutical firms see Zymeworks as one such potential takeover candidate. As we noted in October, it was recently approached about an acquisition valued at roughly $50 per share. Plus, the company just hired a new CEO with a strong background in dealmaking...
This month, Zymeworks announced that CEO Dr. Ali Tehrani is stepping down. Tehrani, who is also a co-founder of the company, has served as CEO since its inception in 2003. The board appointed Ken Galbraith to take his place beginning February 1.
Galbraith's background is telling. He has more than 30 years of experience in the life sciences industry and a notable background in venture capital. That means his skill set is more suitable to dealmaking than Tehrani's.
It makes perfect sense to have a CEO with technical skills like Tehrani's as a company develops its technology. But once that technology has matured, like Zymeworks' has over the past 19 years, a CEO with dealmaking skills like Galbraith's becomes more desirable.